Simcere Of China Seeks To Buy 90 Percent Of Shares In Jilin Boda
This article was originally published in PharmAsia News
Executive Summary
China's Simcere Pharmaceutical Group plans to increase its share of Jilin Boda Pharmaceutical to 90 percent, well beyond its current 51 percent stake